Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. 22, ... a leading global specialty pharmaceutical company, and Rhythm, a ... an exclusive option to acquire Rhythm,s wholly owned subsidiary, ... peptide ghrelin agonist, for the treatment of diabetic gastroparesis ... has completed a successful Phase 2 trial of relamorelin ...
(Date:10/22/2014)... The North American crystal oscillator market report defines ... and forecast of revenue. This market was valued at ... $623.6 million by 2018, at a CAGR of 3.3% ... of the North American crystal oscillator market report, to ... also provides a glimpse of the segmentation of the ...
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... system receives Health Canada clearance to treat severe ... vascular dyschromia and wrinkles, MOUNTAIN VIEW, Calif., Aug. ... and market leader of aesthetic,laser skin treatments, today announced ... the recent Health Canada Clearance. The Canadian,debut of the ...
... Pork Back to Farm of Origin, NORTHFIELD, ... Brand, a leader in premium, all-natural fresh pork, ... DNA for reliable and accurate,traceability back to the ... use IdentiGEN,s DNA TraceBack(R) system, a USDA Process,Verified, ...
... ReceptorBio,Inc. announced today that it has entered into ... (Nasdaq: TELK ) that would enable ReceptorBio ... insulin,receptor activators. These compounds were identified through the,application ... provides for payments related to regulatory milestones and,royalties ...
Cached Biology Technology:Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing 2Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing 3Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing 4Nature's Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity 2Nature's Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity 3Nature's Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity 4ReceptorBio Announces Diabetes License Agreement With Telik 2ReceptorBio Announces Diabetes License Agreement With Telik 3
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... Scientists have sequenced the house fly genome for the ... expect from an insect that thrives in pathogen-rich dung ... 14 in the journal Genome Biology , will ... of how flies quickly adapt to resist insecticides, which ... flies (Musca domestica) carry and transmit more than 100 ...
Breaking Biology News(10 mins):Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2House fly genome reveals expanded immune system 2
... -- Researchers at Polytechnique Montral have succeeded in changing ... transfection method. This major breakthrough in nanosurgery opens the ... treatment of cancers. , A light scalpel to ... Professor Michel Meunier and his team uses a femtosecond ...
... major challenges whether climate change, environmental pollution, urbanisation, ... sweeping shift in our approach to sustainability research ... European policy makers today during the launch of ... for our Unstable Earth" (RESCUE). A joint initiative ...
... series of 15 scientific papers published this week in ... Genetics and G3: Genes|Genomes|Genetics ) put ... called the Collaborative Cross a "library" of genetic ... about genetics and disease into new discoveries, tests, and ...
Cached Biology News:Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3North Carolina-based genetic resources fuel big scientific progress 2North Carolina-based genetic resources fuel big scientific progress 3
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Biology Products: